Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Megan Coylewright

Interventional Cardiology Calhoun, GA Medical Doctor

NPI 1003961772 CMS profile 961512

1035 Red Bud Rd Ne, Calhoun, GA 30701

Open in the dashboard

General payments

$270,788

374 records reported · program years 2019–2025

Research payments

$76,566

Paid to them · 34 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,985,961 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Megan Coylewright of Calhoun, GA is reported in the CMS Open Payments database as having received $270,788 across 374 general payments and $76,566 in research payments paid to them. Separately, studies naming them as principal investigator received $1,985,961 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57,355 54
2025 Research $32,725 9
2024 General $132,290 116
2024 Research $29,200 11
2023 General $16,304 60
2023 Research $8,691 7
2022 General $26,351 66
2022 Research $5,525 6
2021 General $26,213 56
2021 Research $425 1
2020 General $2,250 1
2019 General $10,025 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Coylewright
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Megan Coylewright were reported at $57,355. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Megan Coylewright Interventional Cardiology median Middle half National median
2019 $10,025 $1,097 $329–$3,048 $163
2020 $2,250 $473 $161–$1,480 $114
2021 $26,213 $677 $233–$1,827 $132
2022 $26,351 $978 $333–$2,724 $149
2023 $16,304 $1,136 $382–$2,986 $160
2024 $132,290 $1,181 $395–$3,326 $164
2025 $57,355 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $186,333 176 payments
  2. Edwards Lifesciences Corporation $59,255 88 payments
  3. Medtronic, Inc. $15,848 44 payments
  4. Abbott Laboratories $3,543 40 payments
  5. Recor Medical Inc $2,867 6 payments
  6. W. L. Gore & Associates, Inc. $1,125 1 payment
  7. Medtronic Vascular, Inc. $650 1 payment
  8. Shockwave Medical, Inc $221 3 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $176 2 payments
  10. Abiomed $165 2 payments
  11. Other $604 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $139,269 55 payments
  2. Consulting Fee $87,563 23 payments
  3. Travel and Lodging $22,666 81 payments
  4. Food and Beverage $14,381 210 payments
  5. Honoraria $6,125 2 payments
  6. Grant $785 3 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System Watchman_Ic $85,633 83 payments
  2. WATCHMAN FLX $26,400 24 payments
  3. VersaCross Access Solution $15,101 5 payments
  4. General - Therapies $12,836 14 payments
  5. WATCHMAN WATCHMAN Pro_IC $10,026 6 payments
  6. CoreValve Evolut $8,497 16 payments
  7. Baylis Medical Company Radiofrequency Puncture Generator $7,500 2 payments
  8. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $7,220 18 payments
  9. WATCHMAN Structural Heart $5,250 3 payments
  10. WATCHMAN Access System Structural Heart $4,500 2 payments
  11. Other $17,964 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $76,566 34 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

27

Median for Interventional Cardiology: 2,236

Drug cost

$201

Median for Interventional Cardiology: $380,412

Branded share of claims

0%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 12 $158
Amlodipine Besylate Generic 15 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

408 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record